Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Furst

Showing results (211-220 of 251) with videos related to

Pageof 26
Sort By:
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Annals of the Rheumatic Diseases|July 10, 2004
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritisJ van Holten, K Pavelka, J Vencovsky, et al.
Annals of the Rheumatic Diseases|October 14, 2006
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006D E Furst, F C Breedveld, J R Kalden, et al.
Arthritis and Rheumatism|June 16, 2001
A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaJ E Pope, N Bellamy, J R Seibold, et al.
The Journal of Rheumatology|March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosisJ R Seibold, P J Clements, D E Furst, et al.
Annals of the Rheumatic Diseases|August 14, 2016
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by BoersP Emery, C O Bingham, G R Burmester, et al.
Annals of the Rheumatic Diseases|May 12, 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III studyP Emery, C O Bingham, G R Burmester, et al.
The New England Journal of Medicine|November 30, 2000
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupP E Lipsky, D M van der Heijde, E W St Clair, et al.
Annals of the Rheumatic Diseases|July 27, 2006
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testM H Buch, C P Denton, D E Furst, et al.
Rheumatology (Oxford, England)|January 8, 2008
Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panelD E Furst, R J Halbert, C O Bingham, et al.
Pageof 26

Showing results (211-220 of 251) with videos related to

Sort By:
Pageof 26
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Annals of the Rheumatic Diseases|July 10, 2004
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritisJ van Holten, K Pavelka, J Vencovsky, et al.
Annals of the Rheumatic Diseases|October 14, 2006
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006D E Furst, F C Breedveld, J R Kalden, et al.
Arthritis and Rheumatism|June 16, 2001
A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaJ E Pope, N Bellamy, J R Seibold, et al.
The Journal of Rheumatology|March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosisJ R Seibold, P J Clements, D E Furst, et al.
Annals of the Rheumatic Diseases|August 14, 2016
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by BoersP Emery, C O Bingham, G R Burmester, et al.
Annals of the Rheumatic Diseases|May 12, 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III studyP Emery, C O Bingham, G R Burmester, et al.
The New England Journal of Medicine|November 30, 2000
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupP E Lipsky, D M van der Heijde, E W St Clair, et al.
Annals of the Rheumatic Diseases|July 27, 2006
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testM H Buch, C P Denton, D E Furst, et al.
Rheumatology (Oxford, England)|January 8, 2008
Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panelD E Furst, R J Halbert, C O Bingham, et al.
Pageof 26